Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.
Entera Bio's Capital Expenditure for the
three
months ended in Sep. 2024 was $0.00 Mil. Its Revenue for the
three
months ended in Sep. 2024 was $0.04 Mil.
Hence, Entera Bio's Capex-to-Revenue for the
three
months ended in Sep. 2024 was 0.00.
Entera Bio Capex-to-Revenue Historical Data
The historical data trend for Entera Bio's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Entera Bio's Capex-to-Revenue
For the Biotechnology subindustry, Entera Bio's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entera Bio's Capex-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entera Bio's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where Entera Bio's Capex-to-Revenue falls into.
Entera Bio Capex-to-Revenue Calculation
Entera Bio's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entera Bio (NAS:ENTX) Capex-to-Revenue Explanation
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
Entera Bio Capex-to-Revenue Related Terms
Thank you for viewing the detailed overview of Entera Bio's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ENTX has been successfully added to your 